Drugs / MS-20
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable4 trials | ||||||
| — | NCT04909034 | Aug 2021 → Oct 2024 | non-small cell lung carcinoma | Microbio Co Ltd | Completed | No outcome recorded |
| — | NCT04908644 | Aug 2021 → Nov 2024 | ulcerative colitis | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT04600154 | Aug 2021 → Jun 2023 | chemotherapy-induced toxicity, malignant pancreatic neoplasm | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT04674839 | Oct 2019 → Sep 2020 | — | Microbio Co Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00707681 Comparator | Mar 2008 → Dec 2010 | hepatocellular carcinoma | Microbio Co Ltd | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MS-20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04909034 ↗ |
| Known as | MicrSoy-20 | “Fermented soybean extract MicrSoy-20(MS-20), which uses a variety of lactic acid bacteria and yeasts to metabolize organic soybeans” NCT04908644 ↗1“MicrSoy-20 (MS-20), a fermented soymilk product, has been approved as an Over the counter (OTC) drug in 2011.” NCT04674839 ↗ |
| Action | Activate | “MS-20 has also been shown to be anti-PD-1 booster by activating tumor-infiltrating lymphocytes (TILs) in mice cancer models” NCT04909034 ↗ |
| Modality | Other / unclassified | “fermented soymilk product” NCT04674839 ↗ |
| Route | Oral | “MS-20 or placebo will be orally administered twice per day in treatment period.” NCT04600154 ↗ |